Suprefact (buserelin acetate)
/ Sanofi
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
177
Go to page
1
2
3
4
5
6
7
8
January 16, 2026
Reproductive efficiency of Bos indicus cows under different estradiol-free ovulation synchronization protocols.
(PubMed, Theriogenology)
- "On D0, cows received one intravaginal P4 device and estradiol benzoate (EB; Control) or buserelin acetate (GnRH/EC and 2GnRH). 2). In conclusion, removal of estradiol in ovulation synchronization protocols resulted in lower fertility relative to E2-based controls."
Journal
January 05, 2026
Effect on insulin clearance of different pharmacological treatments in women with polycystic ovary syndrome: a hypothesis-generative study.
(PubMed, J Endocrinol Invest)
- "The impairment of MCRI, which contributes to the hyperinsulinemia typical of PCOS, significantly improved after treatment with metformin. This effect was only partially explained by the reduction of BMI, whereas changes in insulin sensitivity did not show a mediation effect in this phenomenon, suggesting that other metformin-induced mechanisms are involved."
Journal • Polycystic Ovary Syndrome
December 31, 2025
Optimal timing for triggering oocyte maturation during in vitro fertilization cycles varies between gonadotropin-releasing hormone agonist and human chorionic gonadotropin use.
(PubMed, F S Rep)
- "The subjects were categorized into the following two groups according to the type of oocyte maturation trigger used: GnRHa group (buserelin [600 μg] nasal spray) and hCG group (hCG [3,000-10,000 IU] or choriogonadotropin alfa [250 μg] subcutaneously)...Although the MII ratio per oocyte did not show significant difference with the interval duration, the blastocyst formation rate and total number of blastocysts were markedly higher when the interval was longer than 36.5 hours in the GnRHa group. The optimal interval varies between the GnRHa trigger and the hCG trigger, with the hCG trigger associated with a shorter interval for obtaining the maximum number of MII oocytes than the GnRHa trigger."
Journal • Preclinical • Gynecology
December 16, 2025
Association of buserelin acetate with estradiol benzoate in early resynchronization of Bos taurus beef heifers improved conception rates.
(PubMed, Theriogenology)
- "A total of 656 heifers underwent a first fixed-time artificial insemination (FTAI; designated as D0) and received a reused intravaginal progesterone (P4; 1 g) device on D22. The GnRH + EB group achieved a superior pregnancy rate at R22 (EB = 40.8 % vs. GnRH + EB = 56.0 %; P = 0.008) and a higher cumulative pregnancy rate (EB = 68.4 % vs. GnRH + EB = 79.2 %; P = 0.01). In conclusion, the administration of 10 μg of buserelin acetate combined with 1 mg of EB at the beginning of the R22 protocol improved conception rates in Bos taurus beef heifers."
Journal
December 05, 2025
Estradiol esters are dispensable in progesterone-based TAI protocols for Bos taurus suckling beef cows.
(PubMed, Anim Reprod Sci)
- "Also, on D0, cows in the Control group received 2 mg of estradiol benzoate IM and cows in the GnRH/GnRH and GnRH/EC groups received 20 µg of buserelin acetate IM. No difference was observed in the estrus rate before TAI (D9; 72.1, 62.4 and 67.9 %; P = 0.22) or in the pregnancy rate (56.9, 53.1 and 53.6 %; P = 0.77) for control (n = 153), GnRH/EC (n = 147) and GnRH/GnRH (n = 155), respectively. In conclusion, estradiol replacement by GnRH in TAI protocols does not affect LF diameter, estrus expression and pregnancy rate in suckling Bos taurus beef cows."
Journal
November 28, 2025
Pharmacokinetic Evaluation of Buserelin Acetate (Receptal) in Gilts.
(PubMed, J Vet Pharmacol Ther)
- "The clearance rate (CL) was 0.20 ± 0.03 L/h/kg, and the apparent volume of distribution (Vd) was 0.13 ± 0.05 L/kg. These results suggest that buserelin acetate from Receptal is rapidly metabolized and eliminated in gilts, emphasizing the need for precise timing of administration to maintain effective drug concentrations."
Journal • PK/PD data
October 24, 2025
Hormone responses to buserelin in polycystic ovary syndrome and in eumenorrheic women with hyperandrogenism/hyperandrogenemia, and the relationship of these responses with insulin resistance.
(PubMed, J Clin Transl Endocrinol)
- "However, IR presence impacted on more parameters in PCOS than EuHyperA. Given the known ovary sparing by IR in PCOS, it appears that IR exacerbates androgen production of PCOS women more markedly than EuHyperA women."
Journal • Polycystic Ovary Syndrome
October 17, 2025
RTOG 0815: Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
(clinicaltrials.gov)
- P3 | N=1538 | Completed | Sponsor: Radiation Therapy Oncology Group | Active, not recruiting ➔ Completed
Trial completion • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor
October 17, 2025
Estradiol treatment and double dose of GnRH for resynchronization protocols and timed artificial insemination in lactating dairy cows.
(PubMed, Theriogenology)
- "The aim of this study was to compare pregnancy per AI (P/AI) in resynchronization (Resynch) protocols using different hormonal combinations (estradiol benzoate [EB], a double dose of GnRH, or EB with a double dose of GnRH) administered on the day of progesterone (P4) device insertion...The secondary objective was to compare P/AI in cows treated with two different GnRH agonists (gonadorelin acetate or buserelin acetate) on the day of P4 device insertion...In conclusion, the combined administration of EB and a double dose of GnRH does not improve P/AI compared with the administration of either hormone alone. Furthermore, both agonists produced comparable P/AI, confirming that they are equally effective when administered during P4 device insertion."
Journal
October 17, 2025
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
(clinicaltrials.gov)
- P3 | N=239 | Completed | Sponsor: Radiation Therapy Oncology Group | Active, not recruiting ➔ Completed | Trial completion date: Jun 2029 ➔ Sep 2025
Trial completion • Trial completion date • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor
October 13, 2025
Effect of EC-GnRH34 timed AI protocol on ovulation synchrony and fertility in crossbred Girolando dairy cows.
(PubMed, Trop Anim Health Prod)
- "At the IPD removal, all cows were treated with 1 mg i.m estradiol cypionate (EC), and then allocated into two groups to receive either 2.5 mL of saline solution (EC-Control, n = 111) or 10.5 μg i.m. buserelin acetate (GnRH analogue) 34 h after IPD removal (EC-GnRH34, n = 115). In conclusion, the present study demonstrated that the ovulation synchrony is optimized with the use of GnRH 34 h after IPD removal. Fertility to the TAI protocol, however, was not significantly improved in comparison with cows treated with a single ovulation inducer, EC."
Journal
September 27, 2025
Evaluation of Permeation Enhancers for Vaginal Delivery of Buserelin Acetate Using a Validated Chromatographic Method and Ex Vivo Porcine Model.
(PubMed, Pharmaceutics)
- "Kinetic modelling indicated a non-Fickian, biphasic permeation mechanism best described by the Makoid-Banakar model. These findings highlight chitosan's potential as an effective intravaginal delivery vehicle for peptide therapeutics and establish the validated HPLC method as a reliable platform for future formulation development and translational studies in mucosal drug delivery."
Journal • Preclinical
September 12, 2025
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
(clinicaltrials.gov)
- P3 | N=2753 | Active, not recruiting | Sponsor: NRG Oncology | Recruiting ➔ Active, not recruiting
Enrollment closed • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor • CD4
September 13, 2025
Reducing Hormonal Inputs in Rabbit Reproduction: Physical Ovulation Induction with a 3D-Printed Cannula.
(PubMed, Animals (Basel))
- "Two insemination methods were compared: a physical stimulation technique using the 3D-printed cannula and a control method involving hormonal induction with buserelin acetate...This hormone-free approach offers a promising and welfare-friendly alternative for rabbit artificial insemination, aligning with efforts to reduce hormone use in livestock production. Further optimization of cannula design and technique may improve results, particularly in less responsive groups, supporting sustainable and ethical reproductive management."
Journal • Preclinical
September 05, 2025
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
(clinicaltrials.gov)
- P3 | N=192 | Recruiting | Sponsor: Proton Collaborative Group | Trial primary completion date: Dec 2025 ➔ Dec 2027
Trial primary completion date • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor
August 28, 2025
Transplantation of Tissue from Native and Cryopreserved Pekin Duck Ovaries to Mulard Ducks with Study of Hormonal Changes After Grafting.
(PubMed, Animals (Basel))
- "Estrogen levels were elevated in the recipients with adherence but were lower than in the control Pekin group, while progesterone levels remained unchanged. Consequently, recipients received buserelin acetate, a GnRH analogue, to stimulate follicular and oviductal activity...The hormonal levels of the recipients with adhered ovaries were elevated, but the GnRH analogue treatment did not affect the ovulation process. We conclude that while the Mulard duck shows potential as a sterile recipient in ovarian transplantation, several questions remain unanswered regarding the adequacy of follicular maturation and ovulation."
Journal • Transplantation
August 23, 2025
The influence of serum luteinising hormone concentrations post GnRH agonist trigger on metaphase II oocytes in IVF/ICSI cycles.
(PubMed, Eur J Obstet Gynecol Reprod Biol)
- "No LH threshold at 12 h post-GnRHa trigger predicted optimal or suboptimal oocyte maturation. Routine post-trigger LH measurement lacks clinical utility for predicting mature oocyte yield in PCOS IVF/ICSI cycles."
Journal • P2 data • Polycystic Ovary Syndrome
August 05, 2025
Long-acting progesterone supplementation and administration of gonadotropin releasing hormone in early diestrus improves pregnancy rates in Nellore cows with low body condition score and subjected to timed artificial insemination.
(PubMed, Trop Anim Health Prod)
- "After TAI (Day 0), 863 cows were assigned to three groups: P4LA (n = 281; 150 mg long-acting progesterone injection on Day 7), GnRH (n = 285, 10 µg buserelin acetate on Day 7), and control (n = 297; no supplementation). The conception rates of the low-BCS cows were lower in the control group than in the treatment group (P = 0.01). In conclusion, administering GnRH or P4LA on D7 post-TAI enhanced P4 concentrations and improved conception rates in Nellore cows with a low BCS."
Clinical • Journal
July 13, 2025
Breeding and Ontogeny of the Aquarium-Traded Scissortail Rasbora (Rasbora trilineata).
(PubMed, Animals (Basel))
- "Fishes of the genus Rasbora in the Cyprinidae family comprise 88 species [...]."
Journal
July 11, 2025
Adverse event profile differences among long-acting gonadotropin-releasing hormone analogs: A real-world, pharmacovigilance study.
(PubMed, PLoS One)
- "Significant disparities exist between the adverse event profiles of long-acting GnRHa. The identification of high-risk factors and the enhancement of AEs monitoring are crucial during clinical application."
Adverse events • Journal • Real-world evidence • Breast Cancer • CNS Disorders • Endocrine Disorders • Endometriosis • Gastroenterology • Gastrointestinal Disorder • Genito-urinary Cancer • Gynecology • Mental Retardation • Oncology • Pediatrics • Prostate Cancer • Psychiatry • Solid Tumor • Uterine Leiomyoma • Women's Health
July 03, 2025
Buserelin shortens the estrus-to-ovulation interval and improves the pregnancy outcomes in gilts treated with a fixed-time artificial insemination.
(PubMed, Front Vet Sci)
- "Additionally, although the pregnancy rate and farrowing rate didn't differ between the two analogs, buserelin administration is beneficial for the number of total piglets and the piglet index. In conclusion, our data demonstrate that buserelin has advantages in centralizing induced ovulation and thus improving FTAI outcomes."
Journal
June 14, 2025
Supplementation of boar semen extender with 5 μg of buserelin improves litter size and birth weight in gilts raised under tropical field conditions.
(PubMed, Theriogenology)
- "In sows, no significant improvements were observed. These results suggest that supplementing semen with low-dose GnRH analog can improve gilt productivity under tropical conditions and merits further investigation."
Journal
June 12, 2025
A prospective randomized trial comparing dephereline and busereline for ovulation induction in heat-stressed lactating dairy cows.
(PubMed, J Reprod Dev)
- "The likelihood of pregnancy in multiple-ovulating cows was significantly higher in the DEPH group than the BUS group. Collectively, our results comparing two ovulation inducers showed that dephereline treatment may improve the fertility of lactating dairy cows under HS conditions."
Journal
May 16, 2025
Effect of hCG administration on corpus luteum development and plasma progesterone concentration in llamas.
(PubMed, Theriogenology)
- "After induction of ovulation with buserelin (Day 0), llamas were randomly assigned to one of four groups: hCG3 (n = 5), hCG4 (n = 5), hCG5 (n = 5) or control (n = 5), receiving an injection of 750 IU of hCG on Day 3, 4 or 5 or 1.5 ml of saline solution, respectively. Plasma P4 concentration post-mating tended to be greater in pregnant treated llamas than in non-treated pregnant females. These results suggest that hCG administration on Day 4 has a luteotropic effect."
Journal
May 04, 2025
Reproductive outcomes of prepubertal Bos indicus beef heifers raised in a feedlot system submitted or not to ovulation induction strategies prior to a timed-artificial insemination treatment regimen.
(PubMed, Theriogenology)
- "Reproductive outcomes were evaluated in prepubertal Nelore (Bos indicus) heifers submitted or not to two ovulation induction treatment regimens based on progesterone (P4) and estradiol treatments prior to the timed-artificial insemination (TAI)...The TAI was conducted 2 d later (Day 9, 46-50 h after P4 device withdrawal), concurrently with the administration of 8.4 μg of buserelin acetate...In conclusion, although the two ovulation induction treatments imposed prior to the synchronization for TAI resulted in a larger proportion of heifers with CL on Day 0, enhanced UT development and improved expression of estrus, there was no improvement in fertility outcomes of prepubertal Nelore heifers managed in a feedlot system. Interestingly, heifers that did not respond to the ovulation induction treatments (without CL on Day 0) were least fertile, indicating that these heifers were not in a peri-pubertal state, rather, the reproductive endocrine status of these..."
Journal
1 to 25
Of
177
Go to page
1
2
3
4
5
6
7
8